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A B S T R A C T
The aim of the current study is to identify distinct cytokine profiles in relation to self-perceived cognitive tra-
jectories. In our study cohort (n = 128), early-stage breast cancer patients were categorized into no impairment
reported, acute, delayed, persistent and intermittent cognitive decline respectively. Pro-inflammatory cytokines
were elevated compared to baseline; with TNF-α implicated in the acute cognitive trajectory while IL-6 and IL-8
were involved in the persistent cognitive trajectory. Our findings help to further our understanding of cytokine
profiles implicated in cancer-related cognitive impairment (CRCI) and support the use of cytokine levels as
biomarkers of cognitive decline over time.
1. Introduction
Cancer-related cognitive impairment (CRCI) is a problem widely
reported by cancer patients prior, during and after treatment, with a
detrimental impact on their quality of life (Janelsins et al., 2014; Wefel
et al., 2015). While the underlying etiology of CRCI is multifactorial,
immune function has often been proposed as a key contributing factor
(Olson and Marks, 2019). The upregulation of intrathecal cytokine
production and immune cell recruitment in combination with a dis-
ruption of the blood brain barrier (BBB) occurs during neuroin-
flammation (Lepennetier et al., 2019). Cytokines which play an im-
portant role in cell signaling to regulate immune response is of research
interest (Ren et al., 2017). They may elicit local inflammation through
oxidative and nitrosative processes or induce a state of chronic in-
flammation which may affect neuronal and glial cell functioning (Lange
et al., 2019; Olson and Marks, 2019). Given that most of the current
chemotherapeutic drugs are not known to penetrate the blood brain
barrier (BBB) due to their large molecular sizes, it has been postulated
that tumor biology and/or cancer treatment itself trigger downstream
pro-inflammatory pathways that lead to neurological changes via cy-
tokines (Cheung et al., 2013). Alternatively, chemotherapy-induced
oxidative stress may have altered the structure and integrity of the BBB,
leading to an amplified release of cytokines (Gaman et al., 2016). Such
a candidate mechanism for change has also been supported by animal
studies, in which neurobiological changes that underlie cognitive
changes are found to be a result of increased peripheral inflammation
and disrupted BBB in rodent tumor models (Santos and Pyter, 2018). In
the context of inflammation, peripheral cytokine dysregulation has
been shown to induce cognitive changes (Craig J Wilson et al., 2002).
To date, several clinical studies conducted in breast cancer patient
cohorts (Cohen et al., 2019; Lyon et al., 2016; Patel et al., 2015;
Williams et al., 2018) and imaging studies (Kesler et al., 2013;
Pomykala et al., 2013) had reported elevated levels of pro-in-
flammatory cytokines to be positively associated with cognitive deficits.
Cytokines appeared to have a role in cell-signaling in neural commu-
nication relating to cognitive processes in other neurological disease
states such as Alzheimer's disease (Taipa et al., 2019). Distinct cytokine
profiles had been reported for patients who showed resilience to Alz-
heimer's disease, in which there had been an upregulation of cytokines
in the affected brain regions, suggesting an inflammation resolving
microenvironment (Barroeta-Espar et al., 2019). In particular, our re-
search group had previously reported elevated concentrations of IL-6
and IL-1β to be observed in breast cancer patients with poorer response
speed performance and perceived cognitive disturbances in a cohort
study (Cheung et al., 2014a). While many studies had shown how cy-
tokine levels correlate with cognition, there had been wide inter-
individual variability and the implicated cytokines identified tend to
differ between studies. To bridge the gap in our understanding, there
presents a need to evaluate the cytokines beyond their inflammatory
nature.
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Given that the degree of CRCI had been found to differ over time
and during patients' treatment trajectories, our research group had
previously characterized self-perceived cognitive trajectories into five
distinctive types (Ng et al., 2018). There were patients who did not
report any self-perceived cognitive impairment during the study period
compared to patients who experienced cognitive impairment during
varying phases of treatment ranging from the early phase, after the end
of treatment to during survivorship respectively. Cognitive decline of
some sub-group of patients also did not follow any patterns of treatment
trajectory. The existence of heterogenous cognitive trajectories seemed
to suggest that the biomechanisms underlying different CRCI trajec-
tories may differ. In order to evaluate the role for cytokines as per-
ipheral inflammatory mediators that may directly or indirectly influ-
ence cognition, this study aims to identify distinct cytokine profiles
across the varying self-perceived cognitive trajectories. Identifying the
cytokines that correlate with CRCI over time may serve as potential
biomarkers and may help us understand how cytokines may influence
neuroinflammation and contribute to CRCI. These findings will have
clinical application in allowing us to devise targeted management
strategies to mitigate CRCI, considering that a large proportion of
cancer patients are long-term survivors.
2. Material and methods
2.1. Study design
This was a multicentre prospective cohort study conducted between
2014 and 2017. The study was approved by the Singhealth Institutional
Review Board (CIRB 2014/754/B) and written informed consent was
obtained from all participants.
Patients were eligible if they satisfied the following inclusion cri-
teria: (i) at least 21 years of age, (ii) diagnosed with early-stage breast
cancer, (iii) scheduled to receive chemotherapy with curative intent,
(iv) had no prior history of chemotherapy and/or radiation therapy and
(v) able to understand either English or Chinese. Patients who had in-
complete blood samples, did not complete questionnaires at all the
assessed time points, or clinically diagnosed with neurocognitive dis-
orders such as Alzheimer's disease, dementia, depression and/or an-
xiety disorder, were excluded from data analysis.
2.2. Study procedure
Patients were tasked to complete the study questionnaire at the
following time points: baseline, prior to start of chemotherapy (T1),
approximately 6 weeks after chemotherapy initiation (T2), approxi-
mately 12 weeks after chemotherapy (T3) and a post 1-year follow-up
after end of treatment (T4). Relevant demographic and clinical data
were collected through patient interviews and electronic health records.
A 10-mL blood sample was drawn from each patient at T1, T2 and T3.
2.3. Cognitive impairment
For the evaluation of cognitive function, Functional Assessment of
Cancer Therapy-Cognitive Function (FACT-Cog) (version 3) was used. It
is a validated questionnaire used to assess the impact on patient's
quality of life within the past 7 days (Vardy et al., 2006). The minimal
clinical important difference (MCID) approach was used to categorize
patients into status of cognitive impairment, based on a difference of
10.6 points reduction in the global FACT-Cog score between the as-
sessed time points (Cheung et al., 2014b). Each of the patient was ca-
tegorized into five distinct types of cognitive trajectories: no clinically
significant cognitive impairment reported during the study period,
acute (clinically significant cognitive decline reported at either T2 or
T3, but not at T4), delayed (clinically significant cognitive decline re-
ported at only T4), persistent (clinically significant cognitive decline
reported at both T3 and T4) and intermittent decline (clinically
significant cognitive decline reported at T2 and T4, but not at T3) (Ng
et al., 2018).
2.4. Quantification of cytokines
At each assessed time point, a 10-mL blood sample was collected in
ethylenediaminetetraacetic acid (EDTA) tube in the morning. The
timing of blood collection had been standardized in order to minimize
diurnal variation from affecting the fluctuation of measured cytokine
levels (Haack et al., 2004). The blood sample was centrifuged at
2500 rpm for 10 min within 30 min of collection and stored at −80 °C
until further analysis. A multiplex panel of cytokine consisting granu-
locyte-macrophage colony-stimulating factor (GM-CSF), interferon
(IFN)-ƴ, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-2, IL-4,
IL-6, IL-8, IL-10 was quantified using 50 μL of each sample via the
Luminex immunoassay, in duplicate readings. The readings with coef-
ficient of variation above 15% were not included, while samples that
were below the lower limit of quantification were replaced with zeros
(Cheung et al., 2014a). Cytokines were classified based on their im-
munological function: Pro-inflammatory cytokines would include IFN-
ƴ, TNF-α, IL-1β, IL-6 and IL-8 while those belonging to the anti-in-
flammatory category include GM-CSF, IL-2, IL-4 and IL-10 (Cohen et al.,
2019; Henneghan et al., 2018).
2.5. Statistical analysis
Descriptive statistics was used to summarize the demographics,
clinical characteristics and prevalence of cognitive impairment of the
study cohort. The Kolmogorov-Smirnov test was conducted to test for
the normality of the distribution of the dependent variables. The cy-
tokine levels across time points were subsequently trended by their
immunological function and trajectories, in medians (interquartile
range, presented as first quartile - third quartile). Friedman test was
used to compare the change in levels of the respective cytokine levels
across the time points, followed by post-hoc Wilcoxon sign rank tests
between the time points, with Bonferroni correction. The non-para-
metric Mann-Whitney U test was used to compare difference in cytokine
levels between cognitively impaired and non-cognitively impaired
group, where appropriate. All statistical analyses were carried out using
SPSS version 23.0, with two-sided p-values less than 0.05 considered as
statistically significant.
3. Results
3.1. Clinical and demographic characteristics
Out of the total of 217 participants recruited, 128 patients with
complete blood samples and questionnaires were analyzed (Fig. 1). The
age and years of education, expressed in mean ± standard deviation
(SD), were 51.8 ± 8.9 and 10.8 ± 3.4 years respectively. Majority of
the patients were Chinese (82.8%), had stage II breast cancer (68.7%)
and received anthracycline-based chemotherapy (68.0%) (Table 1).
With reference to baseline, there was a greater proportion of patients
with self-perceived cognitive impairment with time: 15.6% at T2,
18.8% at T3 and 32.0% at T4. The proportion of patients with self-
perceived impairment by the varying trajectories were as follows:
59.4% reported no cognitive decline, 15.6% reported delayed impair-
ment, 12.5% reported persistent impairment, 8.6% reported acute im-
pairment while 3.9% reported intermittent impairment (Table 2). There
were no major differences in baseline demographic between the tra-
jectory groups (Supplementary Table 1) or treatment profiles between
the cognitively impaired and non-cognitively impaired group (Supple-
mentary Table 2).
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3.2. Respective cohort cytokine levels across time points
The plasma levels of the cohort's pro-inflammatory cytokines were
plotted across timepoints (Supplementary Fig. 1). In terms of pro-in-
flammatory cytokines, significant changes over time were identified in
median levels (interquartile range) of IFN-ƴ (T1: 2.29 (0.18–13.15) pg/
mL, T2: 1.60 (0.00–13.30) pg/mL and T3: 2.20 (0.09–17.32) pg/mL,
p = .039), TNF-α (T1: 6.07 (1.94–14.65) pg/mL, T2: 5.50 (1.30–17.78)
pg/mL and T3: 6.80 (1.77–19.40) pg/mL, p < .001), IL-6 (T1: 0.43
(0.00–1.13) pg/mL, T2: 0.57 (0.00–1.76) pg/mL and T3: 0.64
(0.00–1.87) pg/mL, p = .003) and IL-8 respectively (T1: 3.59
(2.16–4.91) pg/mL, T2: 3.38 (2.14–5.20) pg/mL and T3: 3.67
(2.40–5.33) pg/mL, p= .002) (Table 3). For post-hoc p-values, changes
in cytokine levels were significant at T2 vs T1 for IL-6 (p = .001); at T3
vs T2 for TNF-α (p < .001) and IL-8 (p = .002); at T3 vs T1 for TNF-α
(p = .007) and IL-6 (p = .001).
Conversely, for anti-inflammatory cytokines, significant changes in
median levels of GM-CSF were detected over time (T1: 0.00 (0.00–0.09)
pg/mL, T2: 0.00 (0.00–0.79) pg/mL and T3: 0.00 (0.00–4.58) pg/mL,
p < .001); IL-4 (T1: 0.08 (0.00–0.31) pg/mL, T2: 0.10 (0.00–0.39) pg/
mL and T3: 0.24 (0.00–0.54) pg/mL, p < .001) and IL-10 (T1: 0.00
(0.00–0.00) pg/mL, T2: 0.00 (0.00–0.00) pg/mL and T3: 0.00
(0.00–0.00) pg/mL, p = .011). For post-hoc p-values, changes in cy-
tokine levels were significant at T3 vs T2 for IL-4 (p = .008) and IL-10
(p = .015); at T3 vs T1 for GM-CSF (p = .001) and IL-4 (p < .001).
3.3. Cytokine levels by self-perceived cognitive trajectories
The median cytokine levels for pro-inflammatory TNF-α, IL-6 and
IL-8 were plotted for the self-perceived cognitive trajectories that had
been implicated in the impaired group (Fig. 2).
In terms of cognitive trajectories, for patients who did not report
any impairment during the study period, there were statistically sig-
nificant changes over time identified in median levels (interquartile
range) of the following cytokines: GM-CSF (T1: 0.00 (0.00–0.34) pg/
mL, T2: 0.00 (0.00–1.54) pg/mL and T3: 0.03 (0.00–7.18) pg/mL,
p= .005); TNF-α (T1: 6.97 (1.94–16.69) pg/mL, T2: 7.13 (1.05–19.05)
pg/mL and T3: 8.53 (1.92–22.80) pg/mL, p = .015); IL-4 (T1: 0.12
(0.00–0.29) pg/mL, T2: 0.17 (0.00–0.44) pg/mL and T3: 0.27
(0.00–0.56) pg/mL, p = .011); IL-6 (T1: 0.49 (0.00–1.20) pg/mL, T2:
0.57 (0.00–1.67) pg/mL and T3: 0.61 (0.04–2.32) pg/mL, p= .032); IL-
8 (T1: 3.89 (2.12–5.18) pg/mL, T2: 3.65 (2.15–5.28) pg/mL and T3:
4.09 (2.44–5.55) pg/mL, p= .045) and IL-10 (T1: 0.00 (0.00–0.00) pg/
mL, T2: 0.00 (0.00–0.00) pg/mL and T3: 0.00 (0.00–0.00) pg/mL,
p = .025) (Table 4). For post-hoc p-values, changes in cytokine levels
were significant at T3 vs T2 for TNF-α (p = .011), IL-8 (p= .012), at T3
vs T1 for IL-4 (p < .001).
For patients in the acute impairment trajectory, there were statis-
tically significant changes identified in median levels of pro-in-
flammatory TNF-α (p = .017). In comparison to the patient group who
did not report cognitive impairment, the absolute levels for those in
Fig. 1. Flow diagram for number of subjects analyzed (n = 128).
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acute impairment trajectory (referred earlier) were lower across all
three time points (T1: 3.75 vs 6.97 pg/mL, p= .47; T2: 3.30 vs 7.13 pg/
mL, p = .61; T3: 5.11 vs 8.53 pg/mL, p = .66). For post-hoc p-values,
change in cytokine levels between timepoints was not found to be
significant.
For patients in the persistent impairment trajectory, there were
changes over time identified for the following cytokines: GM-CSF
(p = .013), IL-1β (p = .017), IL-4 (p < .001), IL-6 (p= .002) and IL-8
(p = .028). The changes in pro-inflammatory IL-1β levels (T1: 0.14
(0.00–0.40) pg/mL, T2: 0.13 (0.02–0.26) pg/mL and T3: 0.29
(0.00–6.01) pg/mL); IL-6 (T1: 0.35 (0.00–1.29) pg/mL, T2: 0.77
(0.13–1.96) pg/mL and T3: 1.21 (0.50–2.82) pg/mL) and IL-8 (T1: 3.14
(2.72–4.31) pg/mL, T2: 3.12 (2.18–4.52) pg/mL and T3: 3.28
(2.69–5.35) pg/mL) were reported to be elevated. For post-hoc p-va-
lues, changes in cytokine levels were significant at T2 vs T1 for IL-6
(p = .013); T3 vs T2 for IL-4 (p = .010); T3 vs T1 for IL-4 (p = .002)
and IL-6 (p = .002).
In comparison to the non-cognitively impaired patient group, the
differences between cytokine levels for persistent impairment trajectory
(referred earlier) were not statistically significant: anti-inflammatory
GM-CSF (T1: 0.00 vs 0.00 pg/mL, p = .56, T2: 0.00 vs 0.00 pg/mL,
p = .66 and T3: 0.00 vs 0.03 pg/mL, p = .76); anti-inflammatory IL-4
(T1: 0.01 vs 0.12 pg/mL, p = .53, T2: 0.00 vs 0.17 pg/mL, p = .17 and
T3: 0.29 vs 0.27 pg/mL, p = .84); IL-6 (T1: 0.35 vs 0.49 pg/mL,
p = .68, T2: 0.77 vs 0.57 pg/mL, p = .44 and T3: 1.21 vs 0.61 pg/mL,
p= .14) and IL-8 (T1: 3.14 vs 3.89 pg/mL, p= .50 T2: 3.12 vs 3.65 pg/
mL, p = .38 and T3: 3.28 vs 4.09 pg/mL, p = .67).
For cognitive impairment that were of delayed onset and inter-
mittent trajectories, no statistically significant changes were observed
with cytokine levels over time.
For visual comparison, the cytokine levels were plotted on the
logarithmic scale across the five self-perceived cognitive trajectory
(Supplementary Fig. 2) and for the individual cytokines
(Supplementary Fig. 3).
4. Discussion
In our cohort of early-stage breast cancer patients, 40.6% of patients
(n = 52) had reported some type of self-perceived cognitive impair-
ment during the study period. We had observed significant changes in
cytokine levels across the different phases of the patient's treatment.
Among the participants who had reported cognitive impairment,
median cytokine levels were elevated at T3 compared to baseline for:
pro-inflammatory TNF-α (T1: 5.12 pg/mL, T2: 5.53 pg/mL and T3:
5.31 pg/mL), IL-6 (T1: 0.53 pg/mL, T2: 0.87 pg/mL and T3: 0.93 pg/
mL) and anti-inflammatory IL-4 (T1: 0.31 pg/mL, T2: 0.41 pg/mL and
T3: 0.45 pg/mL). Levels of pro-inflammatory IL-8 was elevated for
persistent cognitive impairment group (T1: 3.14 pg/mL, T2: 3.12 pg/
mL and T3: 3.28 pg/mL).
TNF-α is known to trigger signaling in astrocytes and hippocampal
synaptic alteration (Habbas et al., 2015) and higher levels of soluble
TNF-α receptor I and II had been found to be associated with poorer
performance in visual memory (Williams et al., 2018). Likewise, IL-6
triggers inflammation, has been implicated in systemic inflammation in
various diseases and aging (Cohen et al., 2019) and its circulating levels
are suggested to be indicator for cognitive health in healthy adults
(Bradburn et al., 2017). In literature, elevated plasma levels of IL-6 had
been linked to worsening cognitive function, in the domain of executive
function (Meyers et al., 2005). In particular, elevated plasma IL-6 levels
were found to cause hippocampal inflammation that lead to memory
decline experienced by breast cancer patients undergoing radiotherapy
(Shibayama et al., 2019). This finding is also consistent with a previous
study conducted by our research group which showed elevated IL-6
concentration being associated with greater extent of self-perceived
cognitive disturbance and may be attributed as physiological in-
flammatory response to chemotherapy (Cheung et al., 2014a). Our
findings of cytokine elevations in participants who had reported self-
perceived cognitive impairment corroborated with how CRCI is known
to be associated with elevated levels of pro-inflammatory cytokines
(Olson and Marks, 2019).
In our cohort, levels of anti-inflammatory IL-4 were also elevated
compared to baseline. Although IL-4 had been found to be associated
with both immediate and delayed recall in domain of verbal memory
(Henneghan et al., 2018), our previous findings suggested higher con-
centration of IL-4 to be associated with better response speed perfor-
mance over 12 weeks, post-chemotherapy (Cheung et al., 2014a). From
this, we gained an understanding that it will be imperative for us to
consider the balance and/or ratio of the quantitative cytokine levels
rather than evaluating solely based on the nature of the cytokines. In
Table 1
Demographics and clinical information of patients (n = 128).
Characteristic Data (mean ± SD or n
(Frequency in %))
Age (years) 51.8 ± 8.9
Body mass index (kg/m2) 24.4 ± 4.3
Education (years) 10.8 ± 3.4
Education (levels) None 3 (2.3)
Primary 15 (11.7)
Secondary 62 (48.4)
Pre-University 24 (18.8)
Graduate and above 24 (18.8)
Ethnicity Chinese 106 (82.8)
Malay 12 (9.4)
Indian 5 (3.9)
Others 5 (3.9)
Marital status Single 26 (20.3)
Married 90 (70.3)
Divorced 10 (7.8)
Widowed 2 (1.6)
Breast cancer stage I 14 (10.9)
II 88 (68.7)
III 26 (20.3)
ECOG performance status 0 124 (96.9)
1 4 (3.1)
Chemotherapy regimen Anthracycline based 87 (68.0)
Taxane based 41 (32.0)
Radiation exposure Exposure to radiotherapy 87 (68.0)
No exposure to radiotherapy 41 (32.0)
Hormonal therapy On Hormonal Therapy 106 (82.8)
Not on hormonal therapy 22 (17.2)
Menopausal status Pre-menopausal 66 (51.6)
Post-menopausal 62 (48.4)
Table 2
Prevalence of self-perceived cognitive impairment by time points relative to
baseline.
Proportion of patients reporting self-perceived impairment
based on FACT-Cog Total score, N (%)
Timepoint At T2 At T3 At T4
Number of patients 20 (15.6) 24 (18.8) 41 (32.0)
Trajectory From T1-T4
None 76 (59.4)
Acute 11 (8.6)
Delayed 20 (15.6)
Persistent 16 (12.5)
Intermittent 5 (3.9)
Each of the patient was categorized into five distinct types of cognitive tra-
jectories: none (no clinically significant cognitive impairment reported during
the study period), acute (clinically significant cognitive decline reported at
either T2 or T3, but not at T4), delayed (clinically significant cognitive decline
reported at only T4), persistent (clinically significant cognitive decline reported
at both T3 and T4) and intermittent decline (clinically significant cognitive
decline reported at T2 and T4, but not at T3).
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the literature, the relationship between cytokine specificity with neural
networks underlying cognitive function has been proposed to be non-
linear (Henneghan et al., 2018). These other parameters are especially
relevant given how cytokines may interact with other
neurodegenerative biomarkers to influence cognitive functioning
(Henneghan et al., 2020) and work in a network of physiological
pathways to elicit downstream response. In order to fully appreciate the
neurobiological mechanisms underpinning CRCI, differences in changes
in cytokine levels will need to be further delineated.
When stratified by self-perceived cognitive trajectories, TNF-α was
found to differ between acute impaired and non-impaired patient
group, with a higher percentage of elevation in cytokine levels for the
former group. For those who reported acute impairment, the elevation
in cytokine levels between T3 vs T1 was 36.2% compared to 22.3% in
non-impaired group. Between non-impaired and persistent patient
group, anti-inflammatory GM-CSF and IL-4 as well as pro-inflammatory
IL-6 and IL-8 were recurring cytokines affected in both groups.
Although these differences in cytokine levels were not found to be
statistically significant, there remains value in observing the temporal
trends in cytokine levels. The time points at which significant changes
in cytokine levels occur (upon post-hoc corrected tests) were not found
to follow a consistent trend. However, elevations in cytokine levels for
those belonging to persistent cognitive impaired group were high-
lighted: at T2 vs T1, increase in IL-6 was significant (p= .013); at T3 vs
T2, increase in IL-4 levels was found to be significant (p = .010); at T3
vs T1, increase in both IL-4 (p = .002) and IL-6 (p = .002) were sig-
nificant. Upon further investigation, the cytokines implicated in the
different cognitive trajectory profiles appear to share immune cell
profiling as there are similarities in the immunomodulatory pathways
in which they are involved in.
Table 3
Plasma cytokine levels with significant change over time points (n = 128).
Concentration (pg/mL)
Median (interquartile range)
Friedman Test Post-hoc Wilcoxon Sign Rank Test
T1 T2 T3 p-value⁎ T2 versus T1,
p-value
T3 versus T2,
p-value
T3 versus T1,
p-value
Pro-inflammatory
IFN-ƴ 2.29 (0.18–13.15) 1.60 (0.00–13.30) 2.20 (0.09–17.32) 0.039 0.918 0.029 0.102
TNFα 6.07 (1.94–14.65) 5.50 (1.30–17.78) 6.80 (1.77–19.40) 0.001 0.754 < 0.001 0.007
IL-6 0.43 (0.00–1.13) 0.57 (0.00–1.76) 0.64 (0.00–1.87) 0.003 0.001 0.139 0.001
IL-8 3.59 (2.16–4.91) 3.38 (2.14–5.20) 3.67(2.40–5.33) 0.002 0.803 0.002 0.027
Anti-inflammatory
GM-CSF 0.00 (0.00–0.09) 0.00 (0.00–0.79) 0.00 (0.00–4.58) <0.001 0.033 0.101 0.001
IL-4 0.08 (0.00–0.31) 0.10 (0.00–0.39) 0.24 (0.00–0.54) <0.001 0.029 0.008 <0.001
IL-10 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.011 0.112 0.015 0.512
⁎ Bolded are p-values that showed statistical significance. For post-hoc test, corrected p-values are set as < 0.016.
Fig. 2. Pro-inflammatory cytokine levels for affected self-perceived cognitive
trajectories.
The median cytokine levels are plotted along a logarithmic axis. Timepoint 1, 2,
3 and 4 refers to baseline assessment, approximately 6 weeks after che-
motherapy initiation, approximately 12 weeks after chemotherapy and post-
year follow-up after end of treatment respectively. Dashed lines indicate p-va-
lues for change of cytokine level across time points showed statistical sig-
nificance (p < .05).
Table 4
Plasma cytokine levels presented by self-perceived cognitive trajectories.
Trajectory Concentration (pg/mL)
Median (interquartile range)
Friedman Test Post-hoc Wilcoxon Sign Rank Test
T1 T2 T3 p-value⁎ T2 versus T1,
p-value
T3 versus T2,
p-value
T3 versus T1,
p-value
Non-impaired (n = 76)
GM-CSF 0.00 (0.00–0.34) 0.00 (0.00–1.54) 0.03 (0.00–7.18) 0.005 0.076 0.225 0.018
TNF-α 6.97 (1.94–16.69) 7.13 (1.05–19.05) 8.53 (1.92–22.80) 0.015 0.510 0.011 0.018
IL-4 0.12 (0.00–0.29) 0.17 (0.00–0.44) 0.27 (0.00–0.56) 0.011 0.046 0.103 <0.001
IL-6 0.49 (0.00–1.20) 0.57 (0.00–1.67) 0.61 (0.04–2.32) 0.032 0.066 0.090 0.021
IL-8 3.89 (2.12–5.18) 3.65 (2.14–5.28) 4.09 (2.44–5.55) 0.045 0.706 0.012 0.040
IL-10 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.00 (0.00–0.00) 0.025 0.339 0.023 0.140
Acute (n = 11)
TNF-α 3.75 (0.62–11.65) 3.30 (2.00–13.46) 5.11 (0.91–17.68) 0.017 0.284 0.037 0.075
Persistent (n = 16)
GM-CSF 0.00 (0.00–0.00) 0.00 (0.00–1.66) 0.00 (0.00–6.01) 0.013 0.893 0.128 0.018
IL-1β 0.14 (0.00–0.40) 0.13 (0.02–0.26) 0.29 (0.05–0.48) 0.017 0.451 0.036 0.060
IL-4 0.01 (0.00–0.22) 0.00 (0.00–0.24) 0.29 (0.02–0.49) <0.001 0.155 0.010 0.002
IL-6 0.35 (0.00–1.29) 0.77 (0.13–1.96) 1.21 (0.50–2.82) 0.002 0.013 0.088 0.002
IL-8 3.14 (2.72–4.31) 3.12 (2.18–4.52) 3.28 (2.69–5.35) 0.028 0.469 0.039 0.134
⁎ Bolded are p-values that showed statistical significance. For post-hoc test, corrected p-values are set as < 0.016.
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We had observed that pro-inflammatory cytokines implicated in
acute cognitive trajectory (TNF-α) belong to T helper (Th)1 group while
those implicated in the persistent (IL-6, IL-8 and anti-inflammatory GM-
CSF) seemed to belong to Th17 (Kothur et al., 2016). Cytokines be-
longing to Th1 group are known to help with cell-mediated immunity
and act on intra-cellular pathogens which may be processes that take
precedence in the acute phases of immune response. Conversely, cy-
tokines within the Th17 category are typically involved with neu-
trophilic inflammation in which they recruit other inflammatory cells
such as monocytes by GM-CSF secretion and macrophages by IL-1β
signaling. Th17 cells are also important for clearance of extracellular
pathogens, regulation of autoimmunity and are often implicated in
chronic inflammatory disease (Kothur et al., 2016). However, Th17
cells appear to be more stable under acute inflammation whereas under
chronic inflammation, the cells would be vulnerable to display plasti-
city and a mixed phenotype (Maddur et al., 2012). It is proposed that
cytokines of Th1 origin are more directly involved in the acute phase of
CRCI while those that are implicated in the persistent impairment tra-
jectory may be influenced by inflammatory environment and other
factors that may cause a switch to alternative inflammatory cytokines in
Th17 cells. Thus, understanding Th-mediated immunity and the effector
cells related to the cytokines secretion may provide us with additional
insights into the immunopathology of these disorders, and how immune
alterations may contribute to cognitive deficits (Kothur et al., 2016). In
fact, data from one study showed that distinct Th1-and Th17-related
cytokines were able to differentiate the different phenotypes of multiple
sclerosis, a chronic inflammatory disease of the central nervous system
(Arellano et al., 2017). This may imply the value of distinguishing cy-
tokine profiles and their relation to immune cell subtypes during neu-
roinflammation, in the context of CRCI.
In other studies looking at breast, colon and hematological malig-
nancy population, some studies had reported no significant associations
between pro-inflammatory cytokines such as IL-6 with cognitive func-
tion (Williams et al., 2018). Such discrepancy observed could be due to
various factors. Firstly, given that biomarker levels exhibit high inter-
individual variability, we may have to consider cytokine levels in re-
lation to patient related factors like type of cancer and chemotherapy
regimen received as well as biological factors such as levels of available
receptors and physiological fluctuations (Olson and Marks, 2019). The
type of chemotherapy regimen and exposure to certain drugs had been
cited as a contributing factor, in which IL-6 levels were increased in
patients undergoing doxorubicin-based chemotherapy group but were
decreased in the patients receiving cyclophosphamide, methotrexate
and fluorouracil chemotherapy (Janelsins et al., 2012). Secondly, the
cognitive domains assessed may also be a factor. For instance, although
IL-8 was classified as pro-inflammatory and expected to be associated
with cognitive decline, its levels had been reported to be positively
correlated with memory (Olson and Marks, 2019) and optimal levels of
executive function in other studies (Henneghan et al., 2018). Apart
from identifying the cytokine implicated in CRCI, it may be clinically
meaningful for future studies to investigate the extent of difference or
threshold cytokine levels that needed to be exceeded for certain signs
and symptoms of CRCI to manifest. A strength of our study is that we
have considered different trajectories and accounted for baseline mea-
surements of cytokine levels. The temporal relationship between cyto-
kines and CRCI, supported by how different cytokines had been im-
plicated in acute and persistent impairment, further substantiated our
use of cognitive trajectories as a way of classification. A major limita-
tion of our study is the lack of patients' blood samples at T4 that cor-
responded with their cognitive outcome, which made the correlation of
the changes observed in cytokine levels for both delayed and inter-
mittent cognitive trajectories less straightforward. However, there re-
main potential clinical applications in which baseline cytokine levels
may be predictive of cognitive status that take place after a time de-
lay.The use of objective measures could also have been employed for a
more holistic assessment of cognitive performance (Wefel et al., 2011).
Our sample size has been further reduced in number when we further
classified patients into the numerous cognitive trajectories. As such, our
findings may be interpreted as being exploratory in nature and further
studies will be needed to validate our findings in independent patient
cohorts. Future work or more sophisticated statistical analysis may be
needed to further entangle the differences in changes in cytokine levels
and consider how cytokines act in complex networks and/or pathway.
5. Conclusion
This is one of the first study that evaluated changes in cytokines
levels in relation to the self-perceived cognitive trajectories. Pro-in-
flammatory cytokines implicated in the acute (TNF-α) and persistent
cognitive trajectories (IL-6 and IL-8) seemed to share a common trait in
the immune effector cells they are involved in, belonging to Th1 and
Th17 functional groups respectively. Our findings help to further cur-
rent understanding of cytokine profiles implicated in CRCI and support
the use of cytokine levels as predictors of cognitive decline over time.
Funding
National Medical Research Council Grant Singapore (NMRC/CIRG/
1386/2014 and NMRC/CIRG/1471/2017).
Declaration of Competing Interest
None.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jneuroim.2020.577196.
References
Arellano, G., Acuna, E., Reyes, L.I., Ottum, P.A., De Sarno, P., Villarroel, L., et al., 2017.
Th1 and Th17 cells and associated cytokines discriminate among clinically isolated
syndrome and multiple sclerosis phenotypes. Front. Immunol. 8, 753.
Barroeta-Espar, I., Weinstock, L.D., Perez-Nievas, B.G., Meltzer, A.C., Siao Tick Chong,
M., Amaral, A.C., et al., 2019. Distinct cytokine profiles in human brains resilient to
Alzheimer’s pathology. Neurobiol. Dis. 121, 327–337.
Bradburn, S., Sarginson, J., Murgatroyd, C.A., 2017. Association of peripheral Interleukin-
6 with global cognitive decline in non-demented adults: a meta-analysis of pro-
spective studies. Front. Aging Neurosci. 9, 438.
Cheung, Y.T., Lim, S.R., Ho, H.K., Chan, A., 2013. Cytokines as mediators of che-
motherapy-associated cognitive changes: current evidence, limitations and directions
for future research. PLoS One 8, e81234.
Cheung, Y., Ng, T., Shwe, M., Ho, H.K., Foo, K.M., Cham, M.T., et al., 2014a. Association
of proinflammatory cytokines and chemotherapy-associated cognitive impairment in
breast cancer patients: a multi-centered, prospective, cohort study. Ann. Oncol.
1446–1451.
Cheung, Y.T., Foo, Y.L., Shwe, M., Tan, Y.P., Fan, G., Yong, W.S., et al., 2014b. Minimal
clinically important difference (MCID) for the functional assessment of cancer
therapy: cognitive function (FACT-Cog) in breast cancer patients. J. Clin. Epidemiol.
67, 811–820.
Cohen, R.A., Gullett, J.M., Woods, A.J., Porges, E.C., Starkweather, A., Jackson-Cook,
C.K., et al., 2019. Cytokine-associated fatigue prior to, during, and post-che-
motherapy for breast cancer. J. Neuroimmunol. 334, 577001.
Gaman, A.M., Uzoni, A., Popa-Wagner, A., Andrei, A., Petcu, E.B., 2016. The role of
oxidative stress in etiopathogenesis of chemotherapy induced cognitive impairment
(CICI)-“Chemobrain”. Aging Dis. 7, 307–317.
Haack, M., Pollmacher, T., Mullington, J.M., 2004. Diurnal and sleep-wake dependent
variations of soluble TNF- and IL-2 receptors in healthy volunteers. Brain Behav.
Immun. 18, 361–367.
Habbas, S., Santello, M., Becker, D., Stubbe, H., Zappia, G., Liaudet, N., et al., 2015.
Neuroinflammatory TNFalpha impairs memory via astrocyte signaling. Cell. 163,
1730–1741.
Henneghan, A., Palesh, O., Harrison, M., Kesler, S.R., 2018. Identifying cytokine pre-
dictors of cognitive functioning in breast cancer survivors up to 10years post che-
motherapy using machine learning. J. Neuroimmunol. 320, 38–47.
Henneghan, A., Haley, A.P., Kesler, S., 2020. Exploring relationships among peripheral
amyloid Beta, tau, cytokines, cognitive function, and psychosomatic symptoms in
breast cancer survivors. Biol Res Nurs. 22, 126–138 1099800419887230.
Janelsins, M.C., Mustian, K.M., Palesh, O.G., Mohile, S.G., Peppone, L.J., Sprod, L.K.,
et al., 2012. Differential expression of cytokines in breast cancer patients receiving
Y.L. Toh, et al. Journal of Neuroimmunology 342 (2020) 577196
6
different chemotherapies: implications for cognitive impairment research. Support
Care Cancer 20, 831–839.
Janelsins, M.C., Kesler, S.R., Ahles, T.A., Morrow, G.R., 2014. Prevalence, mechanisms,
and management of cancer-related cognitive impairment. Int Rev Psychiatry. 26,
102–113.
Kesler, S., Janelsins, M., Koovakkattu, D., Palesh, O., Mustian, K., Morrow, G., et al.,
2013. Reduced hippocampal volume and verbal memory performance associated
with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated
breast cancer survivors. Brain Behav. Immun. 30 (Suppl), S109–S116.
Kothur, K., Wienholt, L., Brilot, F., Dale, R.C., 2016. CSF cytokines/chemokines as bio-
markers in neuroinflammatory CNS disorders: a systematic review. Cytokine 77,
227–237.
Lange, M., Joly, F., Vardy, J., Ahles, T., Dubois, M., Tron, L., et al., 2019. Cancer-related
cognitive impairment: An update on state of the art, detection, and management
strategies in cancer survivors. Ann. Oncol. 30, 1925–1940.
Lepennetier, G., Hracsko, Z., Unger, M., Van Griensven, M., Grummel, V., Krumbholz, M.,
et al., 2019. Cytokine and immune cell profiling in the cerebrospinal fluid of patients
with neuro-inflammatory diseases. J. Neuroinflammation 16, 219.
Lyon, D.E., Cohen, R., Chen, H., Kelly, D.L., McCain, N.L., Starkweather, A., et al., 2016.
Relationship of systemic cytokine concentrations to cognitive function over two years
in women with early stage breast cancer. J. Neuroimmunol. 301, 74–82.
Maddur, M.S., Miossec, P., Kaveri, S.V., Bayry, J., 2012. Th17 cells: biology, pathogenesis
of autoimmune and inflammatory diseases, and therapeutic strategies. Am. J. Pathol.
181, 8–18.
Meyers, C.A., Albitar, M., Estey, E., 2005. Cognitive impairment, fatigue, and cytokine
levels in patients with acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 104, 788–793.
Ng, T., Dorajoo, S., Cheung, Y., Lam, Y.C., Yeo, H.L., Shwe, M., et al., 2018. Distinct and
heterogeneous trajectories of self-perceived cognitive impairment among Asian
breast cancer survivors. Psychooncology 27, 1185–1192.
Olson, B., Marks, D.L., 2019. Pretreatment cancer-related cognitive impairment-me-
chanisms and outlook. Cancers (Basel) 11.
Patel, S.K., Wong, A.L., Wong, F.L., Breen, E.C., Hurria, A., Smith, M., et al., 2015.
Inflammatory biomarkers, comorbidity, and Neurocognition in women with newly
diagnosed breast cancer. J. Natl. Cancer Inst. 107.
Pomykala, K.L., Ganz, P.A., Bower, J.E., Kwan, L., Castellon, S.A., Mallam, S., et al., 2013.
The association between pro-inflammatory cytokines, regional cerebral metabolism,
and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain
Imaging Behav. 7, 511–523.
Ren, X., St Clair, D.K., Butterfield, D.A., 2017. Dysregulation of cytokine mediated che-
motherapy induced cognitive impairment. Pharmacol. Res. 117, 267–273.
Santos, J.C., Pyter, L.M., 2018. Neuroimmunology of behavioral comorbidities associated
with cancer and cancer treatments. Front. Immunol. 9, 1195.
Shibayama, O., Yoshiuchi, K., Inagaki, M., Matsuoka, Y., Yoshikawa, E., Sugawara, Y.,
et al., 2019. Long-term influence of adjuvant breast radiotherapy on cognitive
function in breast cancer patients treated with conservation therapy. Int. J. Clin.
Oncol. 24, 68–77.
Taipa, R., das Neves, S.P., Sousa, A.L., Fernandes, J., Pinto, C., Correia, A.P., et al., 2019.
Proinflammatory and anti-inflammatory cytokines in the CSF of patients with
Alzheimer’s disease and their correlation with cognitive decline. Neurobiol. Aging 76,
125–132.
Vardy, J., Wong, K., Yi, Q.L., Park, A., Maruff, P., Wagner, L., et al., 2006. Assessing
cognitive function in cancer patients. Support Care Cancer 14, 1111–1118.
Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B., 2011. International cognition and cancer
task force recommendations to harmonise studies of cognitive function in patients
with cancer. Lancet Oncol. 12, 703–708.
Wefel, J.S., Kesler, S.R., Noll, K.R., Schagen, S.B., 2015. Clinical characteristics, patho-
physiology, and management of noncentral nervous system cancer-related cognitive
impairment in adults. CA Cancer J. Clin. 65, 123–138.
Williams, A., Shah, R., Shayne, M., Huston, A.J., Krebs, M., Murray, N., et al., 2018.
Associations between inflammatory markers and cognitive function in breast cancer
patients receiving chemotherapy. J. Neuroimmunol. 314, 17–23.
Wilson, C.J., Finch, C.E., Cohen, H.J., 2002. Cytokines and cognition–the case for a head-
to-toe inflammatory paradigm. J. Am. Geriatr. Soc. 50, 2041–2056.
Y.L. Toh, et al. Journal of Neuroimmunology 342 (2020) 577196
7
